Apremilast
DrugParticipants will receive apremilast orally.
Other names: Otezla®
NCT Number: NCT04528082
The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to < 18 years of age with oral ulcers associated with Behçet's disease (BD) through week 12.
Interested in participating?
Request Info2 year–17 year
All sexes
Interventional
Phase 3
Hospices Civils de Lyon Hopital Femme Mere Enfant, Bron, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria
Key Exclusion Criteria
Participants will receive apremilast orally.
Other names: Otezla®
Participants will receive the matching placebo orally.
Time frame: Week 0 to Week 12
Time frame: Week 0 to Week 12
Time frame: Week 0 to Week 12
Pain of oral ulcers will be measured by a visual analog scale (VAS). The participants will be asked to place a vertical line on a 100 mm VAS at the point that represents the severity of oral ulcer pain. The scale will range from "no pain" (left hand boundary) to "worst possible pain" (right hand boundary).
Time frame: Week 12
Complete response rate for oral ulcers is defined as the proportion of participants who are oral ulcer free at Week 12.
Time frame: Week 0 to Week 12
Time frame: Week 12
Complete response rate for genital ulcers is defined as the proportion of participants (with genital ulcers at week 0) who are genital ulcer free at Week 12.
Time frame: Week 0 to Week 12
Disease activity is measured by Behçet's Disease Current Activity (BDCAF) scores. The BDCAF consists of 3 component scores: the Behçet's Disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The BDCAI score ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening), and a negative change from baseline indicates improvement. The Patient's Perception of Disease Activity and the Clinician's Overall Perception of Disease Activity were assessed by the subject and the clinician, respectively, using a scale of 1 to 7, where a higher score indicates a higher level of disease activity.
Time frame: Week 12
Time frame: Week 0 to Week 12
The SF-10 Health Survey for Children is a parent-completed survey that contains 10 questions adapted from the Child Health Questionnaire. The SF-10 is intended to produce physical and psychosocial health summary measures. Each of the 10 questions responses is scored with a point value from 1 to 6 (1 is the worst possible condition and 6 is the best possible condition). The SF-10 physical and psychosocial measures are scored such that higher scores indicate more favorable functioning.
Time frame: Up to Week 56
Time frame: Up to Week 56
The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. Number of participants with suicidal ideation or behavior is defined as the number of participants who answer "yes" at any time during the study (up to end of safety follow-up, Week 56) to one of the 10 categories:
Category 1: Wish to be dead Category 2: Non-specific active suicidal thoughts Category 3: Active suicidal ideation with any methods (not plan) without intent to act Category 4: Active suicidal ideation with some intent to act, without specific plan Category 5: Active suicidal ideation with specific plan and intent Category 6: Preparatory acts or behavior Category 7: Aborted attempt Category 8: Interrupted attempt Category 9: Actual attempt (non-fatal) Category 10: Completed suicide
Time frame: Week 0 to Week 52
Tanner Staging of sexual development assessment will be used to assess sexual maturity. Tanner Staging assessment consists of 3 domains (pubic hair, breast development, and other changes) for girls and 4 domains (pubic hair, penis development, testes development, and other changes) for boys. Stages range from 1-5, with 1 indicating preadolescent and 5 adult.
Time frame: Week 0 to Week 56
Time frame: Week 0 to Week 56
Time frame: Week 0 to Week 56
BMI assessed as weight/(height/100)^2
Time frame: Up to Week 52
Time frame: Week 0 and Week 2
Taste and acceptability will be assessed using a questionnaire with a 7-point faces Likert Scale, with 1 ranging from "super bad" to 7 "super good" and questions to determine whether the participants are able to take the treatment medication.
Time frame: Week 0 to Week 12
Contact information is provided by the study sponsor or research team.
Amgen
Industry
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet's Disease (BEAN)
Acronym: BEAN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04334031
Angioedema, Arthritis
Lille, France
View Trial DetailsNCT05879419
Ankylosis, Arthritis
São Paulo, Brazil
View Trial DetailsNCT02648581
Behcet Syndrome, Behçet Disease
Paris, France
View Trial DetailsNCT06386744
Behcet Syndrome, Behçet Disease
Istanbul, Turkey (Türkiye)
View Trial Details